Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BNTC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-2.72
vs -6.80
Q2.23
N/A
-2.83
vs -10.54
Q3.23
N/A
-2.76
vs -7.99
Q4.23
N/A
-2.64
vs -3.40
Q1.24
N/A
-1.64
vs -2.72
Q2.24
N/A
-1.32
vs -2.83
Q3.24
N/A
-0.48
vs -2.76
Q4.24
N/A
-0.36
vs -2.64
Q1.25
N/A
-0.55
vs -1.64
Q2.25
N/A
-0.59
vs -1.32
Sales Growth
YoY
Current
Estimates
Q3.22
NA
472K vs NA
Q4.22
-44%
14K vs 25K
Q1.23
+13%
54K vs 48K
Q2.23
NA
7K vs NA
Q3.23
-100%
NA vs 472K
Q4.23
-100%
NA vs 14K
Q1.24
-89%
6K vs 54K
Q2.24
-100%
NA vs 7K
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-93%
-0.93
vs -0.58
Q2.23
-2307%
-23.07
vs -0.93
Q3.23
-27%
-0.27
vs -23.07
Q4.23
-44%
-0.44
vs -0.27
Q1.24
-37%
-0.37
vs -0.44
Q2.24
-10%
-0.10
vs -0.37
Q3.24
-8%
-0.08
vs -0.10
Q4.24
-10%
-0.10
vs -0.08
Institutionnal Ownership
QoQ
Q1.22
15
15
vs 13
15%
Q2.22
19
19
vs 15
27%
Q3.22
20
20
vs 19
5%
Q4.22
23
23
vs 20
15%
Q1.23
20
20
vs 23
-13%
Q2.23
16
16
vs 20
-20%
Q3.23
1
1
vs 16
-94%
Q2.24
1
1
vs NA
NA
Forecast
NaN%2025-Revenue
-330%2025-EPS
87%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2024-10-15
Now: Outperform
Guggenheim
initialisePrevious: Not converted
2024-09-12
Now: Buy
Piper Sandler
initialisePrevious: Not converted
2024-06-13
Now: Overweight
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.30 ( -2.20%)
Relative Strenght
95
Volume Buzz
-64%
Earning Acce
Yes
Dist 52w H.
20%
247wallst.com
8 hours ago
globenewswire.com
8 hours ago
zacks.com
13 hours ago
seekingalpha.com
23 hours ago
Relative Strength
BNTC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics